RGN-259: The Thymosin β4 Eye Drop That Isn’t TB-500
The most-cited “human Phase 3 data” for thymosin β4 comes from an eye drop — and it does not say what injectable-TB-500 sellers claim it says.
Abstract: RGN-259 is a topical thymosin beta 4 (Tβ4) eye drop that ran real Phase 3 trials for dry eye disease and neurotrophic keratopathy — and it is the source of nearly every “TB-500 has human data” claim you will read. But RGN-259 uses the full 43-amino-acid protein dosed onto the eye, not the injected 7-amino-acid fragment people buy, and even its own trial record is mixed, with narrowly-missed and failed primary endpoints and no FDA approval. This guide separates the real human evidence from how it gets borrowed.
Search “does TB-500 have human trials” and you will quickly land on a reassuring answer: yes, thymosin β4 reached Phase 3. That claim is technically true and almost always misapplied. The Phase 3 program in question is RGN-259, a thymosin beta 4 eye drop — not the injectable peptide sold as TB-500. The distinction is not pedantic. It changes the molecule, the route, and even whether the evidence counts as a win.
This article walks through what RGN-259 is, what its human trials actually showed (graded honestly, including the parts the marketing skips), and the two separate reasons its data does not transfer to an injected vial of “TB-500.” It is written for research and educational use only — not medical advice.
The one thing to know: that “human data” is an eye drop
When a vendor page says thymosin β4 “has human clinical trials” or “reached Phase 3,” the underlying source is the RGN-259 ophthalmic program. RGN-259 is 0.1% synthetic thymosin β4 formulated as a preservative-free eye drop, developed by RegeneRx Biopharmaceuticals and advanced in the U.S. through its ReGenTree joint venture (later carried forward by the Korean firm HLB Therapeutics). It was studied for two surface-of-the-eye conditions: dry eye disease and neurotrophic keratopathy (a rare disorder where corneal nerve damage stops the eye’s surface from healing).
So the strongest human thymosin β4 evidence is real — but it is topical, ocular, and full-length. None of those three things describe a subcutaneous injection of the TB-500 fragment. Anyone using the RGN-259 trials to vouch for injectable healing is borrowing a result from a different molecule given by a different route for a different problem. The broader fragment-versus-whole-peptide issue is covered in our TB4 vs TB-500 explainer; this article is about the specific human program that confusion leans on.
What RGN-259 (topical thymosin β4) actually is
Thymosin β4 is a 43-amino-acid protein found in nearly every cell, where it acts as the body’s main actin-sequestering molecule — it holds the building blocks cells use to crawl, then releases them where movement and repair are needed. Goldstein and colleagues famously described it as an actin-sequestering protein that “moonlights” to repair injured tissue. On the ocular surface, that translates to a plausible mechanism: promote corneal epithelial cell migration, damp inflammation, and reduce cell death so a stalled wound can close.
RGN-259 packages that protein into a sterile, preservative-free drop. Critically, it is the full-length 43-amino-acid Tβ4, manufactured to pharmaceutical standards for an eye indication. It is not the 7-amino-acid actin-binding fragment (the sequence LKKTETQ, residues 17–23) that the research-chemical market sells as “TB-500.” That fragment carries one of Tβ4’s functional regions; the eye-drop carries all of them. Tβ4 is also a beta-thymosin — a structural-repair peptide, biologically unrelated to the immune-signalling alpha-thymosins like thymosin alpha-1, which is a separate and frequently confused class.
The human evidence, graded honestly
Here is where most summaries stop after quoting one flattering number. The full record is more interesting — and more cautionary.
Neurotrophic keratopathy: SEER-1 and the p-value nobody quotes
The headline result people cite comes from SEER-1 (ClinicalTrials.gov NCT02600429), a randomized, double-masked, placebo-controlled Phase 3 trial in patients with Stage 2–3 neurotrophic keratopathy. After four weeks, 6 of 10 RGN-259-treated patients (60%) achieved complete corneal healing versus 1 of 8 on placebo (12.5%) — the “60% vs 13%” line that circulates online.
What the marketing leaves out: the trial enrolled only 18 patients and was closed early because neurotrophic keratopathy is rare and recruitment was slow. With that tiny sample, the primary endpoint missed statistical significance — p = 0.0656 by Fisher’s exact test (Kang et al., 2022). The investigators reported a genuinely encouraging trend: complete healing two weeks after stopping treatment was significant (p = 0.0359), the placebo group’s single healed eye relapsed, and an adjusted analysis suggested treated eyes were roughly 18 times more likely to heal. But “strong trend in 18 patients” is not the same as “proven,” and honest evidence grading has to say so. The result is hypothesis-supporting, not definitive.
The confirmatory trials: one ongoing, one failed
A trend in 18 patients is exactly the kind of finding that larger trials exist to confirm or refute — and the confirmation has not gone cleanly. The program launched two bigger Phase 3 neurotrophic-keratopathy trials, SEER-2 (U.S., ongoing) and SEER-3 (European). HLB Therapeutics reported that SEER-3 missed its primary endpoint — no statistically significant advantage in complete corneal healing at four weeks versus placebo. The company attributed the miss largely to a stronger-than-expected placebo effect: some patients retain enough corneal nerve function to heal on the vehicle drop alone (lubrication helps), which compresses the gap a drug has to beat.
That outcome matters for how you read the SEER-1 number. The single most-quoted “thymosin β4 works in humans” datapoint is a sub-significant signal that a larger sibling trial then failed to reproduce. RGN-259 is not FDA-approved for neurotrophic keratopathy.
Dry eye disease: the ARISE program
For dry eye, RGN-259 ran a series of three Phase 3 trials — ARISE-1, ARISE-2, and ARISE-3 — together enrolling more than 1,600 patients (ARISE-3 alone enrolled roughly 700 across 20 U.S. sites). The honest read here is “mixed.” Across the program, RGN-259 produced statistically significant improvements in several sign and symptom measures — for example, ocular grittiness and discomfort at certain timepoints, including after a controlled adverse-environment challenge — but it did not deliver the clean, repeated co-primary wins on both an objective sign and a subjective symptom that an FDA dry-eye approval typically requires. The result was company-reported encouraging signals, pooled re-analyses, and continued development discussions — not an approval.
Two takeaways from the whole human record: (1) thymosin β4 has been taken seriously enough to run multiple large, well-designed Phase 3 trials, which is more than most “research peptides” can say; and (2) those trials have repeatedly landed on trends and partial endpoints rather than decisive victories. Both halves are true, and only the first half usually gets quoted.
Why none of this validates injectable TB-500
Even if you granted RGN-259 the most generous possible reading, two gaps still separate it from a syringe of TB-500. They stack.
Gap 1 — full-length protein vs fragment. RGN-259 is the complete 43-amino-acid Tβ4. TB-500 is a 7-amino-acid fragment of it. The eye-drop trials tell you about the whole molecule’s anti-inflammatory, pro-migration, and pro-survival regions working together; they say little about a fragment that reproduces only the actin-binding piece. Borrowing the parent’s data for the fragment is the core error dissected in the TB4 vs TB-500 comparison.
Gap 2 — topical ocular vs systemic injection. RGN-259 is dropped onto the corneal surface, acting locally on epithelial cells it directly contacts, at exposures characterised for an eye. A subcutaneous injection aiming to heal a tendon, gut, or muscle is an entirely different pharmacology: different tissue, different dose, different distribution, and no read-across from a four-week corneal-healing endpoint. A drug working on the eye’s surface is not evidence it works when injected for a hamstring.
Put differently: the only genuinely human, controlled thymosin β4 efficacy data we have is for the wrong molecule given by the wrong route relative to what people actually buy and inject. The systemic, musculoskeletal use case for TB-500 remains animal-data-plus-anecdote. The first registered human trial of the injected fragment itself only began recently, and — tellingly — it is a cardiovascular safety study, not a healing-efficacy one, as covered in our piece on the first human TB-500 trial.
What this means for reading a “Phase 3” claim
RGN-259 is a useful stress test for peptide marketing literacy, because the claim built on it (“thymosin β4 has Phase 3 human data”) is true at the word level and misleading at the decision level. Three habits keep you honest:
- Ask which molecule. “Thymosin β4,” “TB4,” and “TB-500” are routinely used as synonyms; they are not. Human ocular data is full-length Tβ4. Confirm the exact peptide before you let a study count.
- Ask which route and indication. A topical corneal-healing trial does not underwrite a systemic injection for tendon repair. Route and target tissue have to match the use being claimed.
- Ask whether the endpoint was actually met. “Phase 3” describes a trial’s stage, not its success. SEER-1 narrowly missed its primary endpoint; SEER-3 failed it. A trial can be large, rigorous, and still negative.
This is the same identity-and-evidence discipline we apply to sourcing. If you are evaluating a research-grade TB-500 or any thymosin product, the molecule’s identity — full 43-amino-acid Tβ4 versus the relabelled fragment — should be confirmed by mass spectrometry, not by the name on the label; our guide to reading a peptide COA covers exactly that check. The same principle that separates RGN-259’s data from a TB-500 vial also separates a verified vial from a mislabelled one. For background on the fragment’s reported (animal-grade) healing rationale, see our TB-500 healing research overview.
FAQ
Is RGN-259 the same as TB-500? No. RGN-259 is a topical eye drop containing the full 43-amino-acid thymosin β4 protein. TB-500 is an injectable 7-amino-acid fragment of that protein. They share one functional region and differ in molecule, route, and evidence base.
Does thymosin β4 have human clinical trial data? Yes, but it is ocular. The human Phase 3 trials are RGN-259 eye drops for dry eye disease (the ARISE program) and neurotrophic keratopathy (the SEER trials). There is no completed human efficacy trial for injected TB-500 used for systemic tissue repair.
Did RGN-259 work? Mixed. Its most-cited neurotrophic-keratopathy result (60% vs 13% healing) narrowly missed statistical significance (p = 0.0656) in an 18-patient trial, and a larger confirmatory trial (SEER-3) missed its primary endpoint. The dry-eye program hit some secondary sign and symptom endpoints but did not earn approval. RGN-259 is not FDA-approved.
Is RGN-259 FDA-approved? No. As of this writing it remains investigational for both dry eye disease and neurotrophic keratopathy.
Why do people cite RGN-259 to sell TB-500? Because it is the only real human Phase 3 thymosin β4 data, and “Phase 3” sounds definitive. The citation skips two things: the data is for the full-length topical drug, not the injected fragment, and several of those trials did not actually meet their endpoints.
Can I use RGN-259 instead of TB-500? RGN-259 is an investigational prescription-style ophthalmic product, not a consumer peptide, and this article is research and educational information rather than guidance to use any compound. The point here is interpretive, not a recommendation.
References
- Kang, S., et al. (2022). 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences, 24(1), 554. doi:10.3390/ijms24010554. PMID 36613994. (SEER-1; NCT02600429.)
- ReGenTree, LLC / RegeneRx Biopharmaceuticals (2021). Additional Results from ARISE-3 and Pooled Data from Three Phase 3 Clinical Trials Using RGN-259 for the Treatment of Dry Eye. Company press release, 14 May 2021. (Company-reported topline; not peer-reviewed.)
- HLB Therapeutics, reported via Ophthalmology Times. RGN-259 misses primary endpoint in European Phase 3 SEER-3 trial of neurotrophic keratopathy. (Company-reported topline; not peer-reviewed.)
- Bock-Marquette, I., et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. doi:10.1038/nature03000. PMID 15565145.
- Goldstein, A. L., Hannappel, E., & Kleinman, H. K. (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429.
- Educational study-synthesis (licensed-MD secondary source), summarising thymosin β4 human ocular, dermal, and cardiac data. Provenance: educational/anecdote, not primary literature.
Research and educational use only. This article summarises published clinical literature and educational sources for informational purposes and is not medical advice. Nothing here is a recommendation to diagnose, treat, cure, or prevent any condition, or to dose any compound. RGN-259 and the peptides discussed are not FDA-approved for these uses. Consult a qualified clinician before acting on any health information. Evidence is graded honestly: where a trial missed its endpoint, was small, or is company-reported rather than peer-reviewed, it is labelled as such.